APA (7th ed.) Citation

JQE, T., ND, M., R, H., H, M., MV, D., S, S., . . . G, K. (2026). Lenvatinib use across multiple cancer types: A single-centre evaluation of dosing patterns, tolerability and opportunities for dose optimisation. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 10781552261459659. https://doi.org/10.1177/10781552261459659

Chicago Style (17th ed.) Citation

JQE, Tan, Modi ND, Hassankhani R, Martin H, Dyk MV, Spencer S, Sallustio BC, and Kichenadasse G. "Lenvatinib Use Across Multiple Cancer Types: A Single-centre Evaluation of Dosing Patterns, Tolerability and Opportunities for Dose Optimisation." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners 2026: 10781552261459659. https://doi.org/10.1177/10781552261459659.

MLA (9th ed.) Citation

JQE, Tan, et al. "Lenvatinib Use Across Multiple Cancer Types: A Single-centre Evaluation of Dosing Patterns, Tolerability and Opportunities for Dose Optimisation." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 2026, p. 10781552261459659, https://doi.org/10.1177/10781552261459659.